• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Meningioma - Pipeline Review, H2 2012 Product Image

Meningioma - Pipeline Review, H2 2012

  • ID: 2366349
  • December 2012
  • 45 pages
  • Global Markets Direct

Meningioma – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Meningioma - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Meningioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Meningioma. Meningioma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Meningioma.
- A review of the Meningioma products under development by companies and universities/research institutes based on information derived from company READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Meningioma Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Meningioma 7
Meningioma Therapeutics under Development by Companies 9
Meningioma Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Meningioma Therapeutics – Products under Development by Companies 14
Meningioma Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Meningioma Therapeutics Development 16
Novartis AG 16
Arno Therapeutics, Inc. 17
Meningioma – Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
AR-42 - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Avastin + Everolimus - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Imatinib + Hydroxyurea - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Hydroxyurea + Verapamil - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
vatalanib - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
bevacizumab - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
pasireotide - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
pasireotide - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Everolimus + Bevacizumab - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Panobinostat + Radiation Therapy - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Meningioma Therapeutics – Drug Profile Updates 38
Meningioma Therapeutics – Discontinued Products 39
Meningioma Therapeutics - Dormant Products 40
Meningioma – Product Development Milestones 42
Featured News & Press Releases 42
Jun 07, 2012: Arno Therapeutics Announces Additional Orphan-Drug Designations For AR-42 In Europe 42
Feb 21, 2012: Arno Therapeutics Receives Two Orphan-Drug Designations For AR-42 To Treat Central-Nervous-System Tumors 42
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 45
Disclaimer 45

List of Tables
Number of Products Under Development for Meningioma, H2 2012 7
Products under Development for Meningioma – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11
Comparative Analysis by Early Clinical Stage Development, H2 2012 12
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Novartis AG, H2 2012 16
Arno Therapeutics, Inc., H2 2012 17
Assessment by Monotherapy Products, H2 2012 18
Assessment by Combination Products, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 23
Meningioma Therapeutics – Drug Profile Updates 38
Meningioma Therapeutics – Discontinued Products 39
Meningioma Therapeutics – Dormant Products 40
Meningioma Therapeutics – Dormant Products (Contd..1) 41

List of Figures
Number of Products under Development for Meningioma, H2 2012 7
Products under Development for Meningioma – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Mid Clinical Stage Products, H2 2012 11
Early Clinical Stage Products, H2 2012 12
Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 18
Assessment by Combination Products, H2 2012 19
Assessment by Route of Administration, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Molecule Type, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 23

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos